Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Over the past several years, specialty medicine has entered a period of sustained acceleration, characterized by an expanding volume of late-stage clinical data, an increasing number of regulatory submissions, and a growing diversity of therapeutic mechanisms reaching the

Advances that once unfolded gradually are now arriving in rapid succession, requiring clinicians, researchers, and health system leaders to reassess standards of care across multiple disease areas continuously. For many in the medical community, keeping pace with this evolution has become an ongoing challenge, as meaningful regulatory decisions and practice-shaping data emerge with increasing frequency.

This momentum is expected to carry forward into early 2026, with the first quarter shaping up to be particularly active across several specialty fields. Multiple FDA decisions anticipated during this period have the potential to introduce first-in-class therapies, expand treatment options for conditions with long-standing unmet need, and further refine regulatory expectations around clinically meaningful endpoints. In this article, we highlight 5 FDA decisions to watch in the coming months, each representing a potential inflection point in its respective disease area. Together, these decisions, listed below in chronological order, underscore both the opportunities and the complexity facing specialty care as therapeutic innovation continues to accelerate.

Company: Travere Therapeutics
PDUFA date: January 13, 2026
Indication: Focal Segmental Glomerulosclerosis

A decision on sparsentan (Filspari) is expected from the US FDA by January 13, 2026. Sparsentan, a dual endothelin A receptor and angiotensin II type 1 receptor antagonist from Travere Therapeutics, was assessed in the phase 3 DUPLEX Study and phase 2 DUET Study, which demonstrated rapid, sustained reductions in proteinuria compared with maximally dosed irbesartan. The FDA accepted Travere’s supplemental New Drug Application for traditional approval in May 2025, initially indicating plans for an advisory committee meeting, which the agency later determined was no longer necessary as of September 10, 2025. If approved, sparsentan would become the first FDA-approved therapy specifically indicated for focal segmental glomerulosclerosis (FSGS).

: FSGS remains a leading cause of kidney failure with no approved disease-specific therapies, leaving clinicians reliant on off-label and often poorly tolerated options. Approval of sparsentan would establish proteinuria reduction as a validated regulatory endpoint in FSGS and provide a non-immunosuppressive, oral treatment option for both adult and pediatric patients at risk of progression.

Understanding Sparsentan in Pediatric FSGS, With Michelle Rheault, MD

2. Sublingual Epinephrine Film (Anaphlym)

Company: Aquestive Therapeutics
PDUFA date: January 31, 2026
Indication: Type 1 Allergic Reactions
Summary: 

A decision on epinephrine sublingual film (Anaphylm) is expected from the US FDA by January 31, 2026. Epinephrine sublingual film, a polymer matrix–based epinephrine prodrug delivered via sublingual film from Aquestive Therapeutics, was assessed in an Oral Allergy Syndrome challenge study and supporting adult and pediatric pharmacokinetic and safety studies, which demonstrated rapid symptom resolution beginning within 2 minutes of administration and pharmacokinetic profiles comparable to traditional epinephrine exposure. The FDA accepted the New Drug Application on June 16, 2025, following positive pre-NDA feedback in December 2024 and completion of a pediatric study announced in April 2025, and assigned a PDUFA target action date of January 31, 2026.

: Anaphylaxis remains a life-threatening condition in which delayed or avoided epinephrine administration is a major contributor to morbidity and mortality, often driven by fear of needles and poor device adherence. Approval of epinephrine sublingual film could alter emergency allergy care by introducing the first orally delivered, device-free epinephrine option, potentially improving real-world access, carriage, and timely treatment across pediatric and adult populations.


Sublingual Epinephrine Film Well Tolerated in Children, With David Golden, MD

Company: Ascendis Pharma
PDUFA date: February 28, 2026
Indication: 

 A decision on TransCon CNP (navepegritide) is expected from the US FDA by February 28, 2026, following a 3-month PDUFA extension announced November 25, 2025, due to a major amendment submitted on November 5, 2025, related to post-marketing requirements. TransCon CNP, a once-weekly investigational prodrug of C-type natriuretic peptide (CNP) from Ascendis Pharma, was assessed in the pivotal phase 3 ApproaCH trial and additional randomized, placebo-controlled studies, which demonstrated increased growth velocity alongside improvements in muscle strength, leg bowing, and health-related burden with a safety profile comparable to placebo. The New Drug Application was originally submitted in 2025, and Ascendis is also planning submission of a European Marketing Authorisation Application in Q3 2025. If approved, TransCon CNP would expand the therapeutic landscape for pediatric achondroplasia with a long-acting, systemic CNP replacement strategy.

: Achondroplasia is a multisystem genetic condition associated with lifelong skeletal, neurologic, respiratory, and functional complications, and current treatment options remain limited. Approval of TransCon CNP could represent a shift toward disease-modifying therapy that addresses not only linear growth but also broader functional and quality-of-life outcomes in affected children.


The Latest on Navepegritide for Children with Achondroplasia, with Carlos Bacino, MD

Company: Bristol Myers Squibb
PDUFA date: March 6, 2026
Indication: Psoriatic Arthritis
Summary: 

A decision on deucravacitinib (Sotyktu) is expected from the US FDA by March 6, 2026. Deucravacitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor from Bristol Myers Squibb, was assessed in the phase 3 POETYK PsA-1 and POETYK PsA-2 trials, which demonstrated statistically significant improvements in ACR20 response at week 16 versus placebo, along with favorable skin, functional, and quality-of-life outcomes. The FDA accepted the supplemental New Drug Application in July 2025. If approved, deucravacitinib would become the first TYK2 inhibitor indicated for psoriatic arthritis, expanding on its September 2022 FDA approval for moderate-to-severe plaque psoriasis.

 Psoriatic arthritis remains a heterogeneous, progressive disease with persistent unmet need for effective oral therapies that balance efficacy with long-term safety. Approval of deucravacitinib could introduce a differentiated oral mechanism distinct from JAK inhibition, offering clinicians an earlier-line systemic option with a safety profile that may be better suited for long-term disease management.


Deucravacitinib, Zasocitinib Validate TYK2 Inhibition in PsA, With Philip Mease, MD

Company: GSK
PDUFA date: March 24, 2026
Indication: 

Cholestatic Pruritus in Primary Biliary Cholangitis


A decision on linerixibat is expected from the US FDA by March 24, 2026. Linerixibat, an ileal bile acid transporter (IBAT) inhibitor from GSK, was assessed in the phase 3 GLISTEN trial, demonstrating clinically meaningful reductions in moderate to severe cholestatic pruritus and associated quality-of-life burden in patients with primary biliary cholangitis (PBC). The FDA accepted the New Drug Application in June 2025, positioning linerixibat as a potential symptom-directed therapy amid a rapidly evolving PBC treatment landscape following the 2024–2025 approvals of seladelpar and elafibranor. If approved, linerixibat would be the first therapy specifically indicated for PBC-associated pruritus in the United States, according to GSK.

 Despite recent disease-modifying approvals, up to half of patients with PBC continue to experience moderate to severe pruritus, a symptom strongly linked to impaired sleep, mental health, and overall quality of life. A targeted antipruritic option such as linerixibat could address a critical residual unmet need that remains largely refractory to current PBC therapies.


GLISTEN: Linerixibat Improves Biomarkers and Itch in Patients With PBC, With Andreas Kremer, MD, PhD, MHBA

Travere Therapeutics. Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS. September 10, 2025. Accessed September 10, 2025. 

https://ir.travere.com/press-releases/news-details/2025/Travere-Therapeutics-Provides-Update-on-FDA-Advisory-Committee-Meeting-for-FILSPARI-sparsentan-in-FSGS/default.aspx

Aquestive Therapeutics. Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions. June 16, 2025. Accessed June 19, 2025. 

https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-fda-acceptance-new-drug-0

Ascendis Pharma. Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia | Ascendis Pharma. Ascendispharma.com. Published November 25, 2025. Accessed December 24, 2025. 

https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-announces-extension-fda-review-period-transcon-cnp

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally. News release. Bristol Myers Squibb. July 21, 2025. 

https://news.bms.com/news/details/2025/Bristol-Myers-Squibbs-Supplemental-New-Drug-Application-sNDA-for-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis-Accepted-for-Review-Across-Four-Regions-Globally/default.aspx

GSK. Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) | GSK. Gsk.com. Published June 2, 2025. Accessed December 24, 2025. 

https://www.gsk.com/en-gb/media/press-releases/linerixibat-new-drug-application-nda-accepted-for-review-by-the-us-fda

Articles

Specialty medicine is experiencing rapid advancements, with increasing late-stage clinical data and regulatory submissions. This acceleration necessitates continuous reassessment of care standards across various disease areas. The momentum is expected to persist into early 2026, with significant FDA decisions anticipated in the first quarter. These decisions could introduce first-in-class therapies, expand treatment options for unmet needs, and refine regulatory expectations. Key decisions include sparsentan for FSGS, sublingual epinephrine film for allergic reactions, navepegritide for achondroplasia, deucravacitinib for psoriatic arthritis, and linerixibat for cholestatic pruritus in PBC.

Explore five pivotal FDA decisions set for early 2026 that could transform specialty medicine and enhance treatment options across various conditions.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Hepatology

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

FDA News

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

 is a double board-certified psychiatrist and addictionologist, and the medical director of 

and a nationally recognized advocate for trauma-informed, evidence-based care

 has shifted again. It no longer looks like a needle or a bag of powder. It looks like a THC vape a teenager buys from a friend. It looks like a cartridge sold behind the counter of a gas station. It looks like a pill ordered online that arrives in packaging designed to feel harmless. In the adolescent units I lead and the treatment centers I walk every morning, these items move through the hands of young people who have no idea what is hidden inside.

I am not speaking in hypotheticals. I am speaking from the rooms where the shock lands. I talk to parents whose sons and daughters never made it to an emergency department. Their children died in bedrooms and dorms and parked cars with no warning at all. EMS often arrives at a scene that feels frozen, the overdose already past the point of return. Families believed they were dealing with occasional cannabis use. The toxicology says otherwise. It reveals synthetic opioids far more potent than anything they had ever imagined.

These compounds are appearing in places no parent would ever suspect. Nitazenes (extremely potent synthetic opioids) are now being hidden inside cartridges marketed as THC. Kratom derivatives like 7-OH are chemically reshaped into substances that bear little resemblance to the plant they came from. Counterfeit pills are arriving through online marketplaces with extraordinary ease. A teenager sees a familiar color or logo and believes they know what they are taking. There is nothing in the appearance that tells them they are holding a lethal analog designed in a clandestine lab.

Not long ago, I admitted a young woman who collapsed minutes after using what she thought was cannabis. Her breathing failed almost instantly. She lived only because someone acted immediately. The toxicology later confirmed a nitazene analog. Her case is not an anomaly. It is a signal. These events are happening quietly and quickly, far from public view.

Healthcare professionals must recalibrate their instincts. Any unknown vape exposure should be treated as a potential opioid poisoning until proven otherwise. We cannot rely on assumptions. We must have naloxone immediately available and be prepared for repeated dosing. If an adolescent presents with sudden respiratory collapse and a history of vaping, opioid toxicity belongs at the top of the differential.

Detection capabilities must evolve as quickly as the chemistry. Real-time aerosol analysis for emerging analogs is becoming essential. Without it, we are operating blind while the compounds become more sophisticated.

Parents and teenagers deserve clarity. No illicit THC vape is safe. No street cartridge is predictable. Testing strips do not detect nitazenes. Education must be direct, repetitive, and impossible to misunderstand.

There is a final truth we must name. This is not an accidental trend. It is a multi-billion-dollar operation moving through transnational pipelines that cut across the southern border, the Caribbean corridors, and the ports along our eastern seaboard. These compounds are not drifting into our communities. They are being delivered with intent. This is an assault on our youth and on the stability of our country. If we fail to respond with precision and urgency, the cost will be measured in families who never had the chance to say goodbye.

. He is board-certified in psychiatry and addiction medicine. He earned his medical degree from the University of Tennessee Health Science Center and an MPH in international health and transnational operations from Tulane University’s School of Public Health.

The opioid crisis has evolved, with synthetic opioids like nitazenes hidden in products such as THC vapes and counterfeit pills, posing a significant threat to adolescents. These substances are often undetectable and lead to fatal overdoses, as seen in cases where young individuals unknowingly consume lethal analogs. Healthcare professionals must adapt by treating unknown vape exposures as potential opioid poisonings and ensuring naloxone is readily available. The crisis is driven by a deliberate, multi-billion-dollar operation, necessitating urgent and precise responses to protect youth and national stability.

Potent synthetic opioids are being disguised in everyday products—from THC vapes to counterfeit pills—putting teens at unseen, lethal risk.

A Crisis in Disguise: How New Synthetic Opioids Are Infiltrating Popular Substances

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

Announced by parent company Agios on December X, 2025, the 

 has approved mitapivat under the brand name AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia.

"Despite its severity, treatments [for thalassemia] have historically been limited, leaving some patients without any options," Hanny Al-Samkari, MD, Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Brigham Cancer Institute and associate professor at Harvard Medical School, said in a statement. "The ENERGIZE and ENERGIZE-T Phase 3 trial results demonstrate that AQVESME can help address anemia, fatigue, and the need for regular transfusions - key challenges of the disease."1

Mitapivat is a small-molecule oral activator of pyruvate kinase R (PKR), which is involved in maintaining the energy, health, and longevity of red blood cells. Mitapivat improves red blood cell survival in 

 by increasing ATP and diminishing sickling via decreases in 2,3-diphosphoglycerate.

The FDA’s decision was based on results from the phase 3 ENERGIZE and ENERGIZE-T trials. ENERGIZE was a double-blind, randomized, placebo-controlled trial conducted across 70 hospitals in 18 countries globally. For inclusion, patients had to be ≥18 years with non-transfusion-dependent alpha- and beta-thalassemia and hemoglobin concentrations of ≤10 g/dL.

In ENERGIZE, patients were randomly assigned in a 2:1 ratio to either mitapivat or placebo, both of which were administered at 100 mg orally twice a day for 24 weeks. The primary endpoint was the change in hemoglobin response from baseline.

Ultimately, 194 patients were enrolled, with 130 assigned to mitapivat and 64 to placebo. A total of 7 patients receiving mitapivat and 1 receiving placebo discontinued treatment. 55 patients in the mitapivat group had a hemoglobin response, compared to 1 in the placebo group (least-squares mean difference, 41%; 95% CI, 32-50; 

 <.0001). Adverse events were reported in 107 patients in the mitapivat arm versus 63 in the placebo arm, with the most common being headache, initial insomnia, nausea, and upper respiratory tract infection. No deaths were reported.

The ENERGIZE-T trial was a global, double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of mitapivat versus placebo in adults with transfusion-dependent alpha- or beta-thalassemia. Investigators randomly assigned patients ≥18 years in a 2:1 ratio to mitapivat 100 mg or placebo twice daily for 48 weeks.

ENERGIZE-T's primary endpoint was transfusion reduction response (TRR), defined as a ≥50% reduction in transfused red blood cell (RBC) units and a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period compared with baseline. Key secondary endpoints were TRR2, a ≥50% reduction from baseline in transfused RBC units in any consecutive 24-week period, TRR3, a ≥33% reduction from baseline in transfused RBC units in weeks 13-48, and TRR4, a ≥50% reduction from baseline in transfused RBC units at weeks 13-48.

A total of 258 patients were randomized, with 171 assigned to mitapivat and 87 to placebo. A TRR was achieved in 30.4% of patients in the mitapivat arm versus 12.6% in the placebo arm. Additionally, statistically significant reductions in transfusion burden were demonstrated by all key secondary endpoints: 13.5% versus 2.3% achieved TRR2; 14.6% versus 1.1% achieved TRR3; 7.6% versus 1.1% achieved TRR4.

"Today is a landmark moment for the thalassemia community, bringing forward an innovative, disease-modifying oral medicine to address the urgent needs of people living with this devastating rare blood disorder," Brian Goff, chief executive officer of Agios, said in a statement. "With this approval, AQVESME becomes the only medicine indicated for the treatment of anemia in both non-tranfusion-dependent and transfusion-dependent alpha- or beta-thalassemia."1

Agios Pharmaceuticals. US FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia. December 23, 2025. Accessed December 24, 2025. 

https://investor.agios.com/news-releases/news-release-details/us-fda-approves-agios-aqvesmetm-mitapivat-treatment-anemia

Agios Pharmaceuticals. Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease. November 19, 2025. Accessed December 5, 2025. 

https://investor.agios.com/news-releases/news-release-details/agios-announces-topline-results-rise-phase-3-trial-mitapivat

Taher AT, Al-Samkari H, Aydinok Y, et al. Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): A phase 3, International, randomised, double-blind, placebo-controlled trial. The Lancet. 2025;406(10498):33-42. 

Cappellini MD, Sheth S, Taher AT, et al. Energize-T: A global, phase 3, double-blind, randomized, placebo-controlled study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. Blood. 2024;144(Supplement 1):409-409. 

The FDA has approved mitapivat, branded as AQVESME, for treating anemia in adults with alpha- or beta-thalassemia. This approval is based on the ENERGIZE and ENERGIZE-T Phase 3 trials, which demonstrated significant improvements in hemoglobin levels and reductions in transfusion needs. Mitapivat, an oral activator of pyruvate kinase R, enhances red blood cell survival by increasing ATP levels. The trials showed a notable hemoglobin response and transfusion reduction in patients treated with mitapivat compared to placebo, marking a significant advancement in thalassemia treatment options.

The FDA has approved small-molecule pyruvate kinase R activator mitapivat for the treatment of sickle cell anemia.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hematology

FDA Approves Mitapivat (AQVESME) for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia

Stone is professor of medicine at Harvard Medical School and the Edward A Fox Chair in Medicine at the Massachusetts General Hospital. He has treated IgG4-related disease (IgG4-RD) since its emergence in recent years and is passionate about educating patients and fellow healthcare providers (HCPs) about the indolent and systemic nature of this disease.

Current Standards of Care in GCA Treatment

This video covers the following questions:

Let’s shift to discuss current treatments. What is the standard of care for GCA? 

While glucocorticoids have been standard of care for patients with GCA, they are known to elevate the risk of cardiovascular, metabolic, and osteoporotic complications. Please share what you have seen in your clinic.

Videos

Video Series

Current Standards of Care in GCA Treatment 

The Physical and Mental Quality of Life Impacts of GCA

How does GCA impact patient quality of life, particularly in terms of their day-to-day experience? (

What are some of the most significant long-term complications associated with untreated or poorly managed GCA?

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Dyslipidemia in 2025: Year in Review

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chronic Kidney Disease

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Alopecia

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Psychological Distress Greater in Patients With Androgenetic Alopecia

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

A multinational survey suggests even slowly progressing C3G and IC-MPGN substantially affect patients, caregivers, and healthcare systems.


C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

C3G, IC-MPGN Report A Disruptive Burden Regardless of Slowed Disease Progression 

Explore the barriers to PCSK9 inhibitors, their underuse, and how addressing misconceptions can enhance patient outcomes in cholesterol management.

Barriers to Using PCSK9-Targeting Therapies

Experts discuss evolving strategies in atherosclerosis prevention, emphasizing early intervention and the importance of cholesterol monitoring for better patient outcomes.

Rethinking Prevention in ASCVD Through Cumulative LDL Exposure

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The MASH/MASLD year in review highlights FDA approvals, resmetirom data, semaglutide, pemvidutide, and advances in fibrosis and noninvasive endpoints in 2025.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASH/MASLD in 2025: Year in Review

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).


IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Podometrics Could Guide IgAN Treatment While Reducing Invasiveness

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

Alopecia in 2025: Year in Review

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

In this segment, the panel discusses how monitoring strategies will need to adapt as B-cell–targeted therapies such as atacicept, sibeprenlimab, and povetacicept move into broader clinical use.

Latest News

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

A Crisis in Disguise: How New Synthetic Opioids Are Infiltrating Popular Substances

FDA Approves Mitapivat (AQVESME) for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia

Current Standards of Care in GCA Treatment

The Physical and Mental Quality of Life Impacts of GCA